|
Spondyloepimetaphyseal dysplasia, Genevieve type
|
0.700 |
GermlineCausalMutation
|
disease |
ORPHANET |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Spondyloepimetaphyseal dysplasia, Genevieve type
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Spondyloepimetaphyseal dysplasia, Genevieve type
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Spondyloepimetaphyseal dysplasia, Genevieve type
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Spondyloepimetaphyseal dysplasia, Genevieve type
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Bone Diseases, Developmental
|
0.300 |
Biomarker
|
group |
CTD_human |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Developmental Disabilities
|
0.300 |
Biomarker
|
group |
CTD_human |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Child Development Deviations
|
0.300 |
Biomarker
|
disease |
CTD_human |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Child Development Disorders, Specific
|
0.300 |
Biomarker
|
disease |
CTD_human |
NANS-mediated synthesis of sialic acid is required for brain and skeletal development.
|
27213289 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Enforced expression of TMEM207 abrogated the binding of WWOX to HIF-1α, increased HIF-1α and GLUT-1 expression, even under normoxic conditions, and promoted tumour growth in a xenoplant assay using SAS tongue squamous cancer cells.
|
29164763 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Combined treatment of CDHP and CDDP significantly suppressed the growth of SAS and HSC2 cells <i>in vitro</i> and that of tumors <i>in vivo</i> compared with the effects caused by single drug only or control treatments.
|
28927087 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SEMA3F shows growth inhibitory activity in SAS and HSC2 cells and may act as a tumor suppressor.
|
29299034 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>In vivo</i>, we found that hcc49scFv-FasL drastically reduced the formation of lymph node metastasis and decreased primary tumor growth in SAS orthotopic and subcutaneous xenograft tumor models.
|
28292939 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, cRGD-CDDP/m rapidly accumulated into the lymph node metastasis of SAS-L1 tumors, effectively inhibiting their growth, and prolonging mice survival.
|
28666729 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In <i>in vitro</i> cultured human OSCC cells (OECM1 and SAS) were employed to test the inhibitory growth of HCD via cell cytotoxic effect using 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay, Western blotting, and further determining of the inhibitory efficacy of tumor growth by a xenograft tumor on BALB/c male nude mice (<i>in vivo</i> test).
|
29108236 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Accordingly, honokiol dose-dependently inhibited the growth of SAS SP xenograft and markedly reduced the immunohistochemical staining of PCNA and endothelial marker CD31 in the xenograft tumor.
|
27012679 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to their basal HIF-1α status, the tumor cell lines were divided into low (SAS, XF354, FaDu, A549, CX-), intermediate (EPLC-272H, BHY), and high (H1339) HIF-1α expressors.
|
22318330 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SAS/neo tumor cells, especially intratumor Q cell populations, showed a marked reduction in sensitivity due to the repair of radiation-induced damage, compared with the total or Q cell populations within SAS/mp53 tumors that showed little repair capacity.
|
17982649 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SAS/mp53 tumors showed larger values for the size of not only the HF but also the diffusion-limited chronically HF than SAS/neo tumors.
|
15380594 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, the efficacy of gene transduction and the tumor-cell killing effect on four human oral (SAS, HSC-2, HSC-3, HSC-4) and one murine squamous cell carcinoma cell (SCC-7, a kind gift of Dr. M. Hiraoka, Kyoto University) lines in vitro with Ad vector conjugated with catioic liposome (Ad/SUV) was evaluated.
|
12798404 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Apoptotic cells were more frequently observed in SAS/neo tumors than in SAS/mp53 tumors in X-ray irradiation but not in C-beam irradiation.
|
12174881 |
2002 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
SAS and CDK4 genes were found to be amplified fourfold in two Grade II tumors and in one dedifferentiated tumor.
|
10943202 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using 146 DNA samples derived from a variety of bone and soft tissue tumors, we have studied the pattern of amplification of these three genes, CDK4, MDM2, and SAS, to investigate whether there are any tumor type specific patterns of amplification.
|
9703873 |
1998 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
It occurs in 15% of glioblastomas and almost always includes the CDK4 and SAS genes, in about 10% of tumors the MDM2 gene, and at lower frequency GLI, GADD153, and A2MR.
|
8586464 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations demonstrate that SAS amplification occurs with a significant frequency in mesenchymal tumors and is particularly associated with abdominal disease.
|
1319830 |
1992 |